Mr. Hasni was first diagnosed with lung cancer in mid-2024, finding a mass in his right lung measuring 2x6x3 cm. Biopsy results showed it was adenocarcinoma with positive EGFR mutation, a high-grade malignancy. Initially, his doctor planned to perform surgery, but this was canceled due to the discovery of metastasis in both the right and left lungs. He was then given targeted chemotherapy drugs.
A CT scan evaluation after two months of targeted therapy revealed that the cancer was still progressing rapidly to 4x7x4 cm, three times the volume compared to two months earlier, with further spread in both lung fields. Mr. Hasni’s condition was worsening rapidly at the same time.
Ultimately, the family looked towards ECCT as a last resort for Innovative Treatment for Lung Cancer. Our medical team advised him to continue the targeted drug treatment while using ECCT. The ECCT device kills high-grade cancer cells relatively quickly (within 1-3 months), and the targeted chemotherapy is effective in suppressing endocytosis responses, allowing the process to proceed smoothly and effectively, preventing a cytokine storm that could cause widespread inflammation.
After three months of using the ECCT device, Mr. Hasni’s cancer shrank to 1x2x1.5 cm, a 97% reduction in volume; significant shrinkage was also observed in the metastasis. Six months after using the device again, the cancer mass was reduced to remnants of calcium (the shell of the cancer) that had yet to be expelled.
After six months of using the device and at 77 years old, he was in excellent health and continue to use ECCT for preventive measure.
Comments